Novo Nordisk Withholding Tresiba From German HTA Process
This article was originally published in The Pink Sheet Daily
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.
You may also be interested in...
The Danish diabetes specialist is preparing to diversify into obesity with the first launches of Saxenda expected in the first half of 2015. Competition is expected to increases for GLP-1 market leader Victoza but Novo Nordisk also expects a more benign U.S. pricing environment during the year.
IQWiG has said that Novo Nordisk's refusal to make public part of its dossier for its diabetes therapy Tresiba represents a lack of transparency and makes the drug impossible to recommend.
The sharing of executive responsibilities with Kare Schultz frees up CEO Lars Sorensen to focus on key growth markets, as Novo Nordisk faces growing competitive pressures from generics, new diabetes market entrants and a tougher pricing environment.